Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-03-06 Major Shareholding Noti…
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
简式权益变动报告书（新意资本基金管理（深圳）有限公司）
Major Shareholding Notification Classification · 100% confidence The document is titled '简式权益变动报告书' which translates to 'Simplified Equity Change Report'. It details changes in shareholding and voting rights of a specific entity (新意资本基金管理（深圳）有限公司) in the listed company 云南生物谷药业股份有限公司. The document includes legal references to court rulings affecting share transfers, detailed tables of shareholding before and after the change, and declarations about the nature and purpose of the equity change. It is a formal report disclosing changes in major shareholding and voting rights, consistent with notifications required when significant share ownership crosses thresholds or changes substantially. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a proxy statement or AGM material. The content matches the definition of a Major Shareholding Notification (MRQ). The document length (over 11,000 characters) and detailed content confirm it is the report itself, not just an announcement of a report publication.
2024-03-06 Chinese
关于股东所持公司部分股份被司法拍卖完成过户暨控股股东、实际控制人发生变更的公告
Major Shareholding Notification Classification · 95% confidence The document is an official announcement from a company regarding the completion of judicial auction and transfer of shares held by certain shareholders, resulting in a change of the controlling shareholder and actual controller of the company. It details the shareholding changes, the judicial auction process, and the impact on the company. There is no financial data, earnings information, or detailed report content. The document is a regulatory announcement about changes in major shareholding and control, not a full report or financial statement. Therefore, it fits best under the category of Major Shareholding Notification (MRQ). The document length is under 5,000 characters, but it contains substantive information about shareholding changes, not just a report publication announcement or a brief notice. Hence, MRQ is the most appropriate classification.
2024-03-06 Chinese
2023年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 Annual Performance Express Report" and contains preliminary financial data for the year 2023, including revenue, net profit, earnings per share, and asset information. It explicitly states that the data is preliminary, unaudited, and subject to change in the formal annual report. The document is relatively short (1895 characters) and serves as a quick earnings update rather than a full annual report. It includes management commentary on performance and risk warnings but lacks detailed audited financial statements or comprehensive analysis. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. It is not the full Annual Report (10-K) or Interim Report (IR), nor is it a report publication announcement (RPA) since it contains substantive financial data, not just a notice of report availability. FY 2023
2024-02-27 Chinese
2023年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast announcement by Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It contains preliminary financial data for the full year 2023, including expected net profit/loss figures and explanations for major changes. The text explicitly states that the data are preliminary, unaudited, and subject to adjustment in the formal 2023 annual report. The document is short (1118 characters) and serves as a performance forecast rather than a full annual report. It is not a full financial report but an earnings preview or earnings guidance. Therefore, it fits best under Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results or forecasts with key highlights only. FY 2023
2024-02-27 Chinese
关于股东所持公司部分股份被司法拍卖的进展公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the judicial auction of shares held by certain shareholders. It details court rulings, execution orders, and the transfer of shares due to legal enforcement actions. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a legal proceeding affecting share ownership and potential control changes. It does not fit into categories like Annual Report, Earnings Release, or M&A filings. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about judicial auction and share ownership changes without fitting other specific categories.
2024-01-31 Chinese
回购股份注销完成暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from a company regarding the completion of its share repurchase and cancellation, including details on the number of shares repurchased, the change in share capital, and subsequent administrative steps. It includes specific data on share quantities before and after cancellation and mentions a confirmation certificate from the securities registration authority. The document length is short (1071 characters), and it is not a full financial report but an announcement about share repurchase and capital changes. Therefore, it fits the category of 'Transaction in Own Shares' (POS).
2024-01-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.